

Article

Not peer-reviewed version

Mental Health and Substance Use Disorders in Transplant Waitlist, VAD, and Heart Transplant Patients: A TriNetX Database Analysis

Chloe Grzyb , [Dongping Du](#) , Balakrishnan Mahesh , [Nandini Nair](#) *

Posted Date: 24 April 2024

doi: 10.20944/preprints202404.1608.v1

Keywords: substance use; cardiac transplant; VAD; mental health



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

Mental Health and Substance Use Disorders in Transplant Waitlist, VAD, and Heart Transplant Patients: A TriNetX Database Analysis

Chloe Grzyb ¹, Dongping Du ², Balakrishnan Mahesh ³ and Nandini Nair ^{1,4,*}

¹ Pennsylvania State University College of Medicine, Hershey, PA 17033 cgrzyb@pennstatehealth.psu.edu

² Department of Industrial Engineering, Texas Tech University, Lubbock, TX 79409 Dongping.du@ttu.edu

³ Division of Cardiothoracic Surgery, Department of Surgery, Penn State Health Milton S Hershey Medical Center, Hershey PA 17033.bmahesh@pennstatehealth.psu.edu

⁴ Division of Cardiology, Department of Medicine, Penn State Health Milton S Hershey Medical Center, Hershey PA 17033 nandini.nair@gmail.com

* Correspondence: nandini.nair@gmail.com; Tel.: +1-6108641687

Abstract: Background/Objectives: Mental health and substance use disorders (MHD, SUD) affect cardiac allograft and VAD recipients and impact their quality of life and compliance. Limited research on MHDs and SUDs in transplant and MCS candidates and recipients. This study compares the incidence of MHDs and SUDs in transplant list, VAD, and post-transplant patients with that in heart failure patients. **Methods** Study cohorts were derived from the TriNetX using ICD-10 codes. Differences in incidence were examined using the log-rank test. Adults with mental health disorders before the window of time were excluded. Propensity score matching was performed using TriNetX to balance demographic and medical comorbidities. Statistical significance was set at $p < 0.05$. All comparisons were made between propensity-matched cohorts. **Results** Transplant waitlist patients showed a statistically significant increase in the incidence of anxiety, panic disorder, adjustment disorder, depression, mood disorder, alcohol use disorder, and eating disorder. Post-transplant patients showed a statistically significant increase in the incidence of depression and opioid use compared to the heart failure population. VAD patients showed a statistically significant increase in the incidence of depression and a statistically significant decrease in panic disorder and anxiety. **Conclusions** The results pave the pathway for further investigations on prevention and coping strategies because deterioration of mental health will significantly impact compliance with medications as well as patient survival and quality of life. The use of opioids for pain management in the early postoperative period should be further investigated to assess its impact on long-term substance use and addiction.

Keywords: substance use 1; cardiac transplant 2; VAD 3; mental health 4

1. Introduction

Patients with advanced heart failure may wait years on the cardiac transplant list before undergoing heart transplantation. Others may be candidates for ventricular assistance devices (VADs) as a bridge to transplant or as a destination therapy. The uncertainty, fear, and medical challenges of these experiences may have a significant impact on patients' mental health. Depression affects up to 60% of solid-organ recipients and most studies suggest depression is an independent risk factor for increased morbidity and mortality after transplant [1–3]. Poor mental health has been shown to decrease treatment compliance and increase hospitalizations/ infectious complications in post-transplant patients [4,5]. Use of immunosuppressive drugs, especially corticosteroids and calcineurin inhibitors, continued medical issues, and health anxiety likely contribute to deterioration in mental and physical health [1].

After cardiac transplantation or VAD implantation, concerns such as diet, adjustment, lifestyle, medication regimen, and follow-up care are closely monitored, especially in the months following surgery. However, psychiatric disorders may present during the pre-operative and anytime in the postoperative course, thus requiring lifelong attention. This emphasizes the need for multidisciplinary care coordination and support for heart failure patients while waiting, before and after surgical intervention. Rehabilitation should not only address physical wellbeing but also cognitive and psychological functioning which are needed to extend beyond the post-operative period.

Elevated rates of depression, anxiety, and decreased QOL have been identified in post-transplant patients and inconsistently in VAD patients [6–8]. However, there is limited evidence as to the effect of other mental health disorders (MHDs) and SUDs. This study compares the incidence of a wide range of MHDs and SUDs in the transplant waitlist, VAD, and post-transplant patients with that of heart failure patients.

2. Materials and Methods

Data from TriNetX was used to derive study cohorts using ICD-10 codes shown in Table 1. The incidence of MHDs and SUDs was compared in adult heart failure with the transplant waitlist, VAD, and cardiac transplant patients within 15 years of the index event. Index events that occurred up to 20 years ago were included. The index event was defined as the time the patient entered the cohort. This was set to the first diagnosis of heart failure for control patients and the date of transplant/VAD insertion or first registration on the cardiac transplant waitlist. Differences in incidence were examined using the log-rank test and hazard ratios. Patients with mental health disorders before the window of time were excluded. Patients between ages 0-100 were included. Propensity score matching was performed using TriNetX to balance demographic and medical comorbidities. Statistical significance was set at $p \leq 0.05$.

Table 1. Diagnosis ICD codes used.

Diagnosis	ICD Codes
Heart failure (LV failure)	I50.1
VAD	Z95.811
Heart transplant list	Z94.1
Heart transplant recipient	33945
Depression	F32, F33
Mood disorder	F39
Anxiety	F41.1
Panic disorder	F41.0
PTSD	F43.1
Adjustment disorder	F43.2
Eating disorders	F50
Somatoform disorders	F50
ADHD	F90
Opioid-use disorders	F11
Alcohol-use disorders	F10
Nicotine dependence	F17
Dementia	F03
Suicidal ideation or self-harm	R45.851, R45.88, T14.91, T50.902, X71-X83

TriNetX is a global health research network that compiles data from the electronic health records of many healthcare organizations. These include large academic medical institutions across the world. The data are stored on servers or through a virtual platform at participating institutions that are subsequently collected and aggregated. The data include demographic characteristics, diagnoses, medications, laboratory values, and procedures. This project included data from the Global Collaborative Network, 30 countries, and 104 healthcare organizations. The database includes insured and uninsured patients. This study is Health Insurance Portability and Accountability Act compliant and was exempt from IRB approval. For outcomes with <10 patients, TriNetX reports a value of 10 patients to protect patient privacy.

3. Results

3.1.1. Transplant Waitlist Patients

After propensity score matching, 29,900 patients were identified in each cohort. The mean ages at the index event were 49.3 +/- 21.5 heart failure and 64.6 +/- 18.7 transplant waitlist patients, respectively. The characteristics of this cohort are shown in Table 2.

Table 2. Propensity score matching for transplant waitlist versus heart failure patients.

Characteristic	Before Matching			After Matching		
	Heart failure patients	Transplant list patients	Standard Difference	Heart failure patients	Transplant list patients	Standard Difference
Age at index, years	49.3 +/- 21.5	69.1 +/- 16.5	1.029	49.4 +/- 21.5	64.6 +/- 18.7	0.755
Male	163210 (57.6%)	20259 (67.7%)	0.208	20361 (68.1%)	20217 (67.6%)	0.01
Race						
White	148374 (52.4%)	17628 (58.9%)	0.131	17576 (58.8%)	17607 (58.9%)	0.002
American Indian or Alaska Native	498 (0.2%)	95 (0.3%)	0.029	99 (0.3%)	95 (0.3%)	0.002
Pacific Islander	1273 (0.4%)	80 (0.3%)	0.31	90 (0.3%)	80 (0.35)	0.006
Black or African American	23891 (8.4%)	5130 (17.1%)	0.263	5291 (17.7%)	5105 (17.1%)	0.016
Asian	7954 (2.8%)	658 (2.2%)	0.39	627 (2.1%)	658 (2.2%)	0.007
Essential hypertension	130274 (46.0%)	10664 (35.5%)	0.213	10906 (36.5%)	10664 (35.7%)	0.017
Neoplasms	61898 (21.9%)	5867 (19.6%)	0.056	5808 (19.4%)	5860 (19.6%)	0.004
Diabetes mellitus	72647 (25.7%)	7237 (24.2%)	0.034	7264 (24.3%)	7224 (24.2%)	0.003
Obesity and overweight	45565 (16.1%)	4255 (14.2%)	0.052	4212 (14.1%)	4249 (14.2%)	0.004

Psychosocial stressors	13436 (4.7%)	899 (3.0%)	0.09	856 (2.9%)	899 (3.05)	0.009
Chronic lower respiratory diseases	60391 (21.3%)	4738 (15.8%)	0.142	4741 (15.9%)	4735 (15.8%)	0.001
Epilepsy or seizures	6007 (2.1%)	689 (2.3%)	0.012	661 (2.0%)	686 (2.3%)	0.017
Cerebral infarction	19796 (7.0%)	1978 (6.6%)	0.015	1845 (6.2%)	1974 (6.6%)	0.018
Ischemic heart diseases	109963 (38.8%)	9370 (31.3%)	0.159	9293 (31.1%)	9368 (31.3%)	0.005
Heart failure	96068 (33.9%)	13166 (44.0%)	0.207	13054 (43.7%)	13120 (43.9%)	0.004
Atrial fibrillation and flutter	69909 (24.7%)	6655 (22.2%)	0.058	6491 (21.7%)	6638 (22.2%)	0.012
Cardiomyopathy	41677 (14.7%)	10244 (34.2%)	0.466	10140 (33.9%)	10198 (34.1%)	0.004
Fibrosis and cirrhosis of live	5393 (1.9%)	1189 (4.0%)	0.123	1052 (3.5%)	1173 (3.9%)	0.021
Chronic kidney disease and acute kidney failure	74403 (26.3%)	9736 (32.5%)	0.137	9711 (32.5%)	9693 (32.4%)	0.001
Number of patients	283188	29946		29900	29900	

Transplant waitlist patients showed a statistically significant increase in the incidence of anxiety, panic disorder, adjustment disorder, depression, alcohol use disorder, and eating disorder. Survival analysis showed a statistically significant impact of anxiety, panic disorder, adjustment disorder, depression, mood disorder, nicotine dependence, opioid use, dementia, and eating disorders on the waitlist patients. Other parameters tested were not significant as shown in Table 3.

Table 3. Incidence of MHDs/ SUDs in transplant waitlist patients versus heart failure patients.

Disorder	Incidence		p-value for incidence analysis	Survival Analysis	
	Incidence in Cardiac Transplant wait, list patients,	Incidence in Control (Heart failure)		Hazard Ratio	Hazard ratio p-value
	Expressed as the total number in propensity-matched cohort	Expressed as the total number in propensity-matched cohort			

Somatoform Disorder	261/29773	144/29759	0.86	1.57	0.4
Anxiety	1289/28969	505/29254	0.001*	1.771	0.003*
Panic Disorder	552/29460	260/29557	0.042*	1.486	0.032*
PTSD	496/29344	205/29645	0.117	1.686	0.079
Adjustment Disorder	1495/28298	638/29269	0.00*	1.742	0.00*
Depression	4293/25149	2194/25819	0.00*	1.5	0.00*
Mood Disorder	600/29587	281/29598	0.126	1.463	0.004*
Nicotine Dependence	1459/27603	1292/24832	0.913	0.706	0.012*
Alcohol Use Disorder	792/28615	785/27658	0.015*	0.685	0.466
Opioid Use	495/29621	276/29460	0.146	1.261	0.00*
Dementia	492/29749	895/29118	0.126	0.261	0.00*
Eating Disorder	264/29734	144/29783	0.011*	1.279	0.025*
Self-Harm	688/29463	574/29302	0.251	0.811	0.487
*p<0.05					

3.1.2. Cardiac Transplant Patients

After propensity score matching, 4,855 patients were identified in each cohort. The only variable that differed significantly between the two groups was age, which was higher in heart failure patients as shown in Table 4. The mean age at index was 68.9 +/- 16.7 for heart failure and 44.8 +/- 20.9 for transplant patients.

Table 4. Propensity score matching for cardiac transplant versus heart failure patients.

Characteristic	Before Matching			After Matching		
	Heart failure patients	Transplant patients	Standard Difference	Heart failure patients	Transplant patients	Standard Difference
Age at index, years	68.9 +/- 16.7	44.8 +/- 20.9	1.274	62.9 +/- 17.3	44.8 +/- 20.9	0.944
Male	164631 (57.7%)	3344 (68.7%)	0.229	3360 (69.2%)	3333 (68.7%)	0.012
Race						
White	149310 (52.4%)	3081 (63.3%)	0.223	3139 (64.7%)	3071 (63.3%)	0.029

American Indian or Alaska Native	507 (.2%)	10 (.2%)	0.006	11 (.2%)	10 (.2%)	0.004
Pacific Islander	1281 (.4%)	10 (.2%)	0.043	10 (.2%)	10 (.2%)	<.001
Black or African American	24349 (8.5%)	1054 (21.7%)	0.373	991 (20.4%)	1051 (21.6%)	0.03
Asian	7967 (2.8%)	84 (1.7%)	0.072	68 (1.4%)	84 (1.7%)	0.027
Essential hypertension	131365 (46.1%)	2937 (60.3%)	0.289	2992 (61.6%)	2937 (60.5%)	0.023
Neoplasms	62477 (21.9%)	1580 (32.5%)	0.239	1571 (32.4%)	1577 (32.5%)	0.003
Diabetes mellitus	73369 (25.7%)	2106 (43.3%)	0.376	2099 (43.2%)	2098 (43.2%)	<.001
Obesity and overweight	46002 (16.1%)	1509 (31.0%)	0.356	1536 (31.6%)	1506 (31.0%)	0.013
Psychosocial stressors	13542 (4.7%)	391 (8.0%)	0.135	348 (7.2%)	391 (8.1%)	0.033
Chronic lower respiratory diseases	60902 (21.4%)	1339 (27.5%)	0.144	1333 (27.5%)	1338 (27.6%)	0.002
Epilepsy or seizures	6062 (2.1%)	208 (4.3%)	0.122	162 (3.3%)	206 (4.2%)	0.047
Cerebral infarction	20026 (7.0%)	853 (17.5%)	0.324	774 (15.9%)	848 (17.5%)	0.041
Ischemic heart diseases	111021 (38.9%)	3002 (61.7%)	0.467	3012 (62.0%)	2999 (61.8%)	0.006
Heart failure	97555 (34.2%)	4512 (92.7%)	1.529	4483 (92.3%)	4500 (92.7%)	0.013
Atrial fibrillation and flutter	70600 (24.8%)	2545 (52.3%)	0.59	2475 (51.0%)	2535 (52.2%)	0.025
Cardiomyopathy	42890 (15.0%)	4089 (84.0%)	1.905	4115 (84.8%)	4077 (84.0%)	0.022
Fibrosis and cirrhosis of live	5488 (1.9%)	383 (7.9%)	0.278	357 (7.4%)	372 (7.7%)	0.012

Chronic kidney disease and acute kidney failure	75401 (26.4%)	3411 (70.1%)	0.971	3389 (69.8%)	3399 (70.0%)	0.004
Number of patients	285200	4867		4855	4855	

Post-transplant patients showed a statistically significant 1.5 to 2-fold increase in the incidence of adjustment disorder, depression, and opioid use compared to the heart failure population as noted in Table 5. Survival analysis showed a statistically significant impact of a heart transplant on adjustment, mood, and opioid use disorders. Other parameters tested were not significant.

Table 5. Incidence of MHDs/ SUDs in cardiac transplant versus heart failure patients.

Disorder	Incidence		P-value for incidence	Survival analysis	
	Incidence in Post heart transplant	Incidence in Control (Heart failure)		Hazard Ratio	Hazard p-value
	Expressed as the total number in the propensity-matched cohort	Expressed as the total number in the propensity-matched cohort			
Somatoform Disorder	66/4822	32/4810	0.425	1.644	0.845
Anxiety	270/4531	138/4658	0.391	1.603	0.059
Panic Disorder	109/4656	63/4757	0.29	1.394	0.067
PTSD	116/4612	72/4781	0.346	1.307	0.737
Adjustment Disorder	292/4108	180/4633	0.046	1.527	0.00*
Depression	645/3416	468/3642	0*	1.217	0.094
Mood Disorder	148/4736	95/4772	0.261	3.191	0.00*
Nicotine Dependence	255/4233	258/3708	0.168	0.671	0.281
Alcohol Use Disorder	134/4456	184/4206	0.64	0.554	0.072
Opioid Use	144/4769	67/4726	0.038*	1.791	0.009*
Dementia	48/4834	168/4693	0.993	0.215	0.878

Eating Disorder	65/4782	42/4810	0.08	1.234	0.462
Self-Harm	134/4707	174/4675	0.123	0.605	0.786
*p<0.05					

3.1.3. VAD Patients

10,659 patients were identified in each cohort after propensity score matching. The VAD cohort was older than the heart failure cohort (61.3 +/- 16.4 versus 34.1 +/- 20.3 years, respectively). Other baseline characteristics shown in Table 6 were comparable between groups.

Table 6. Propensity score matching for VAD versus heart failure patients.

Characteristic	Before Matching			After Matching		
	Heart failure patients	VAD patients	Standard Difference	Heart failure patients	VAD patients	Standard Difference
Age at index, years	34.1 +/- 20.3	61.3 +/- 16.4	1.469	38.1 +/- 22.2	58.2 +/- 17.7	1.004
Male	18737 (34.6%)	17882 (66.6%)	0.675	6700 (62.9%)	6435 (60.4%)	0.051
Race						
White	26699 (50.3%)	17195 (64.0%)	0.28	6320 (59.3%)	6565 (61.6%)	0.047
American Indian or Alaska Native	94 (0.2%)	121 (0.5%)	0.049	53 (0.5%)	48 (0.5%)	0.007
Pacific Islander	52 (0.1%)	63 (0.2%)	0.34	22 (0.2%)	22 (0.2%)	<0.001
Black or African American	9854 (18.6%)	5629 (21%)	0.06	2174 (20.4%)	2096 (19.6%)	0.018
Asian	2205 (4.2%)	430 (1.6%)	0.153	238 (2.2%)	225 (2.1%)	0.008
Essential hypertension	10839 (20.4%)	14295 (53.2%)	0.723	3522 (33.0%)	3163 (29.7%)	0.073
Neoplasms	8744 (16.5%)	7244 (27%)	0.257	1927 (18.1%)	1811 (17.0%)	0.029
Diabetes mellitus	5799 (10.9%)	9246 (34.4%)	0.585	1892 (17.8%)	1764 (16.5%)	0.032
Obesity and overweight	8238 (15.3%)	7305 (27.2%)	0.293	1515 (14.2%)	1536 (14.4%)	0.006
Psychosocial stressors	2631 (5.0%)	1983 (7.4%)	0.101	468 (4.4%)	449 (4.2%)	0.009

Chronic lower respiratory diseases	9088 (17.1%)	6932 (25.8%)	0.213	1615 (15.2%)	1595 (15.0%)	0.005
Epilepsy or seizures	1722 (3.2%)	803 (3.0%)	0.015	322 (3.0%)	275 (2.6%)	0.027
Cerebral infarction	1209 (2.3%)	3359 (12.5%)	0.399	717 (6.7%)	649 (6.1%)	0.026
Ischemic heart diseases	2482 (4.7%)	14479 (53.9%)	1.286	2028 (19.0%)	1899 (17.8%)	0.031
Heart failure	1537 (2.9%)	15385 (57.3%)	1.472	1460 (13.7%)	1551 (14.6%)	0.025
Atrial fibrillation and flutter	1005 (1.9%)	9932 (36.2%)	0.993	915 (8.6%)	1027 (9.6%)	0.037
Cardiomyopathy	774 (1.5%)	9733 (36.2%)	0.993	722 (6.8%)	869 (8.2%)	0.052
Fibrosis and cirrhosis of live	606 (1.1%)	929 (3.5%)	0.155	219 (2.1%)	207 (1.9%)	0.008
Chronic kidney disease and acute kidney failure	2924 (5.5%)	10741 (40.0%)	0.902	1609 (15.1%)	1477 (13.9%)	0.035
Number of patients	53119	26866		10659	10659	

VAD patients showed a statistically significant increase in the incidence of depression and a statistically significant decrease in panic disorder and anxiety. No significant difference was noted in the incidence of somatoform, adjustment, mood, alcohol, eating, opioid disorders, PTSD, nicotine use, or self-harm. Survival analysis (13.6 years) showed a statistically significant impact of anxiety, panic disorder, PTSD, adjustment, depression, eating disorder, self-harm, opioid/alcohol use, and nicotine dependence as noted in Table 7. Interestingly, opioid use in this population seems to confer a survival benefit with a hazard ratio of 0.74. A marginal but significant survival benefit was also noted with nicotine dependence. Both of these factors showed a nonsignificant decrease in incidence in the VAD population.

Table 7. Incidence of MHDs/ SUDs in VAD versus heart failure patients.

Disorder	Incidence		p-value for Incidence analysis	Survival Analysis	
	Incidence in VAD patients	Incidence in Control (Heart failure)		Hazard Ratio	Hazard ratio p-value
	Expressed as the total number in the propensity-matched cohort	Expressed as the total number in the propensity-matched cohort			

Somatoform Disorder	62/10596	64/10568	0.722	1.6	0.642
Anxiety	265/10341	345/10120	0.011*	0.9	0.044*
Panic Disorder	117/10453	127/10453	0.014*	1.1	0.013*
PTSD	125/10456	140/10448	0.056	1.1	0.02*
Adjustment Disorder	429/10209	226/10360	0.087	2.3	0.00*
Depression	1035 /8849	813/8750	0.003*	1.6	0.00*
Mood Disorder	174/10509	95/10496	0.286	2.1	0.82
Nicotine Dependence	452/8868	540/8226	0.212	0.9	0.00*
Alcohol Use Disorder	300/10004	239/9818	0.873	1.4	0.00*
Opioid Use	134/10466	206/10258	0.563	0.74	0.001*
Dementia	166/10500	71/10584	0.598	2.75	0.138
Eating Disorder	63/10592	43/10569	0.779	1.62	0.031*
Self-Harm	207/10404	145/10405	0.057	1.7	0.03*
*p<0.05					

4. Discussion

The majority of studies about mental health and transplant/VAD patients to date focus on depressive and anxiety symptoms in cardiac transplant patients. We have attempted to perform a comprehensive analysis of MHDs and SUDs in three subgroups of heart failure patients using the largest patient cohort size to date.

Transplant list patients:

The waitlist period can last days to years. Absolute contraindications are a history of medical noncompliance and poor social support [9]. Some studies suggest that psychiatric conditions may negatively affect transplant outcomes through poor adherence, self-injurious behaviors, drug interactions, and poor social support on the whole [10].

Our results found that cardiac transplant wait list patients showed a statistically significant increase in the incidence of six psychiatric disorders (anxiety, depression, panic, adjustment, alcohol use, and eating disorders; whereas in the post-transplant patients, significant increases in incidence were noted only in adjustment disorder and depression. In the VAD population significant increase in incidence was only noted in depression while anxiety and panic disorder were significantly decreased.

The trends noted in this study may be because the waitlist period is critical in maintaining eligibility for transplants and a time of uncertainty, fear, and stress. Early diagnosis, treatment, and improved access to resources for patients on the transplant waitlist are critical in improving survival and candidacy for transplant patients. This also highlights inequity between those who may have better social support and increased access to care and resources which need further investigation.

Literature regarding posttransplant outcomes of patients with psychiatric disorders is inconsistent [11]. Studies cite a history of suicide/self-harm, depressive episodes, and poor medical adherence as the greatest factors impacting posttransplant survival time [12,13]. However, a

comprehensive review contradicted these findings, suggesting that there is no clear association between prior psychiatric illness and morbidity and mortality and that patients with psychiatric conditions can have good outcomes after transplant [11,14]. Candidacy for transplant should be made through consideration of individual risk factors, not the presence of psychiatric conditions to avoid stigmatization of this patient population.

Cardiac transplant patients:

Our results found that transplant patients had a significant increase in the incidence of depression and opioid use disorder compared to heart failure patients. This supports existing literature suggesting that transplant increases the risk of depression, often due to difficulty in coping with a lifestyle change and complications [15–17]. Interestingly, it is thought that rates of anxiety and depression are lower in patients receiving heart transplants compared to other cardiac surgeries, including valve replacement [18].

Studies have found cardiac transplant patients are at increased risk (3-10%) of developing opioid use disorder. Severe pain during the recovery period may increase the risk of long-term dependence on opioids [19]. Decreasing the dose and duration of opioids prescribed at discharge may decrease the risk of long-term opioid use and dependence.

VAD patients:

Our results found that VAD patients showed a statistically increased incidence of depression and statistically significant decrease in panic disorder and anxiety following VAD implantation. Some evidence shows an initial improvement in depression and anxiety after implantation, however, patient-reported outcomes remained lower than those of transplant patients [7,20]. Our study looked at the longitudinal development of these disorders on a scale of over ten years, whereas these studies looked at weeks-month long periods. Further investigation into the timing and onset of anxiety and depression is warranted.

VADs increase the risk of PTSD or panic disorder, despite the possibility of acute VAD dysfunction or mechanical failure [7]. Similarly, our results found a statistically significant decrease in the incidence of PTSD and anxiety following VAD insertion compared to heart failure patients. Existing literature is primarily focused on anxiety, depression, and PTSD only.

Studies have found that depression and anxiety increase prior to VAD implantation, decline again after surgery, and resurface with complications and difficulty with adjustment [7,8]. While services are aimed at all phases, counseling, and psychiatric services are generally concentrated around surgical intervention [6,21,22]. Years after the transplant, the patient may still struggle to cope and have recurrent medical complications. Patients with depression have been found to have elevated rates of stroke and sepsis [2]. Resources are most concentrated around the pre- and post-operative period. MHDs and SUDs are known to impact treatment compliance as well as compliance with lifestyle interventions, which is an important factor in predicting survival. Screening, counseling, and pharmacologic treatment should be offered when necessary.

This study was limited by its retrospective nature. Transplant candidates and VAD/transplant recipients may have more frequent interactions with the healthcare system and may be more likely to be diagnosed with a MHD or SUD than patients with heart failure. Some misidentification is possible with use of a large, national database. Because the database was intended for billing purposes, it lacks granularity and may be missing data, which could contribute to underreporting of MHDs/SUDs. We were also unable to account for comorbid SUDs and MHDs. Further studies should assess the time to onset of mental health disorders and trends in correlation with treatment advances. There is also a need to determine the optimal management of patients with pre-existing MHDs in addition to those who develop disorders.

5. Conclusions

These results lay the groundwork for further studies to investigate current prevention and strategies in place for transplant candidates as well as transplant and VAD patients. Increased rates of MHDs and SUDs are likely multifactorial. Early diagnosis, treatment, and improved access to

resources for VAD, transplant candidates, and recipients may improve outcomes. Incorporation of longitudinal psychiatric care may improve patient quality of life and survival.

Author Contributions: Conceptualization, N.N., D.D and B.M.; methodology, C.G, D.D.; software, C.G.; validation, N.N., D.D.; formal analysis, C.G.; Investigation, N.N., D.D and C.G.; resources, N.N.; data curation, N.N.; writing—original draft preparation, C.G; writing—review and editing, N.N; visualization, N.N.; supervision, N.N; project administration, N.N.D.D.; funding acquisition, None for this project. All authors have read and agreed to the published version of the manuscript.”

Funding: “This research received no external funding”

Institutional Review Board Statement: Not applicable as a public database was used

Informed Consent Statement: Not applicable as a public database was used

Data Availability Statement: Data will be made available on request

Conflicts of Interest: None of the authors have any conflicts of interest concerning this work/project.

References

1. Corbett C, Armstrong MJ, Parker R, Webb K, Neuberger JM. Mental health disorders and solid-organ transplant recipients. *Transplantation*. 2013;96(7):593-600. doi: 10.1097/TP.0b013e31829584e0..
2. Alyaydin E, Sindermann JR, Köppe J, Gerss J, Dröge P, Ruhnke T, Günster C, Reinecke H, Feld J. Depression and Anxiety in Heart Transplant Recipients: Prevalence and Impact on Post-Transplant Outcomes. *J Pers Med*. 2023 ;13(5):844. doi: 10.3390/jpm13050844.
3. Dew MA, Rosenberger EM, Myaskovsky L, DiMartini AF, DeVito Dabbs AJ, Posluszny DM, Steel J, Switzer GE, Shellmer DA, Greenhouse JB. Depression and Anxiety as Risk Factors for Morbidity and Mortality After Organ Transplantation: A Systematic Review and Meta-Analysis. *Transplantation*. 2015;100(5):988-1003. doi: 10.1097/TP.0000000000000901.
4. Delibasic M, Mohamedali B, Dobrilovic N, Raman J. Pre-transplant depression as a predictor of adherence and morbidities after orthotopic heart transplantation. *J Cardiothorac Surg*. 2017;12(1):62. doi: 10.1186/s13019-017-0626-0.
5. Pfeifer PM, Ruschel PP, Bordignon S. Estratégias de enfrentamento pós-transplante cardíaco: implicações psicológicas. *Braz J Cardiovasc Surg*. 2013;28(1):61–8. DOI: 10.5935/1678-9741.20130010
6. Tigges-Limmer K, Brocks Y, Winkler Y, Stock Gissendanner S, Morshuis M, Gummert JF. Mental health interventions during ventricular assist device therapy: a scoping review. *Interact Cardiovasc Thorac Surg*. 2018 ;27(6):958-964. doi: 10.1093/icvts/ivy125.
7. Weerahandi H, Goldstein N, Gelfman LP, Jorde U, Kirkpatrick JN, Meyerson E, Marble J, Naka Y, Pinney S, Slaughter MS, Bagiella E, Ascheim DD. The Relationship Between Psychological Symptoms and Ventricular Assist Device Implantation. *J Pain Symptom Manage*. 2017;54(6):870-876.e1. doi: 10.1016/j.jpainsymman.2017.05.002.
8. Bidwell JT, Lyons KS, Mudd JO, Gelow JM, Chien CV, Hiatt SO, Grady KL, Lee CS. Quality of Life, Depression, and Anxiety in Ventricular Assist Device Therapy: Longitudinal Outcomes for Patients and Family Caregivers. *J Cardiovasc Nurs*. 2017;32(5):455-463. doi: 10.1097/JCN.0000000000000378..
9. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, Danziger-Isakov L, Kirklin JK, Kirk R, Kushwaha SS, Lund LH, Potena L, Ross HJ, Taylor DO, Verschuuren EAM, Zuckermann A; International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases, Pediatric and Heart Failure and Transplantation Councils. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. *J Heart Lung Transplant*. 2016 ;35(1):1-23. doi: 10.1016/j.healun.2015.10.023.
10. Kop WJ. Role of psychological factors in the clinical course of heart transplant patients. *J Heart Lung Transplant*. 2010;29(3):257-60. doi: 10.1016/j.healun.2009.10.013.
11. Rosenberger EM, Dew MA, Crone C, DiMartini AF. Psychiatric disorders as risk factors for adverse medical outcomes after solid organ transplantation. *Curr Opin Organ Transplant*. 2012;17(2):188-92. doi: 10.1097/MOT.0b013e3283510928.
12. Owen JE, Bonds CL, Wellisch DK. Psychiatric evaluations of heart transplant candidates: predicting post-transplant hospitalizations, rejection episodes, and survival. *Psychosomatics*. 2006 ;47(3):213-22. doi: 10.1176/appi.psy.47.3.213.

13. Faeder S, Moschenross D, Rosenberger E, Dew MA, DiMartini A. Psychiatric aspects of organ transplantation and donation. *Curr Opin Psychiatry*. 2015;28(5):357-64. doi: 10.1097/YCO.000000000000185.
14. Zimbrea P, Emre S. Patients with psychotic disorders in solid-organ transplant. *Prog Transplant*. 2015 ;25(4):289-96. doi: 10.7182/pit2015296.
15. Zipfel S, Schneider A, Wild B, Löwe B, Jünger J, Haass M, Sack FU, Bergmann G, Herzog W. Effect of depressive symptoms on survival after heart transplantation. *Psychosom Med*. 2002 ;64(5):740-7. doi: 10.1097/01.psy.0000031575.42041.6a.
16. Dew MA, Kormos RL, Roth LH, Murali S, DiMartini A, Griffith BP. Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation. *J Heart Lung Transplant*. 1999 ;18(6):549-62. doi: 10.1016/s1053-2498(98)00044-8.
17. Dew MA, Rosenberger EM, Myaskovsky L, DiMartini AF, DeVito Dabbs AJ, Posluszny DM, Steel J, Switzer GE, Shellmer DA, Greenhouse JB. Depression and Anxiety as Risk Factors for Morbidity and Mortality After Organ Transplantation: A Systematic Review and Meta-Analysis. *Transplantation*. 2015 ;100(5):988-1003. doi: 10.1097/TP.0000000000000901.
18. Heilmann C, Kaps J, Hartmann A, Zeh W, Anjarwalla AL, Beyersdorf F, Siepe M, Joos A. Mental health status of patients with mechanical aortic valves, with ventricular assist devices and after heart transplantation. *Interact Cardiovasc Thorac Surg*. 2016;23(2):321-5. doi: 10.1093/icvts/ivw111.
19. Brown CR, Chen Z, Khurshan F, Groeneveld PW, Desai ND. Development of Persistent Opioid Use After Cardiac Surgery. *JAMA Cardiol*. 2020 ;5(8):889-896. doi: 10.1001/jamacardio.2020.1445.
20. Brouwers C, Denollet J, de Jonge N, Caliskan K, Kealy J, Pedersen SS. Patient-reported outcomes in left ventricular assist device therapy: a systematic review and recommendations for clinical research and practice. *Circ Heart Fail*. 2011;4(6):714-23. doi: 10.1161/CIRCHEARTFAILURE.111.962472..
21. Willemsen D, Cordes C, Bjarnason-Wehrens B, Knoglinger E, Langheim E, Marx R, Reiss N, Schmidt T, Workowski A, Bartsch P, Baumbach C, Bongarth C, Phillips H, Radke R, Riedel M, Schmidt S, Skobel E, Toussaint C, Glatz J. Rehabilitationsstandards für die Anschlussheilbehandlung und allgemeine Rehabilitation von Patienten mit einem Herzunterstützungssystem (VAD - ventricular assist device) [Rehabilitation standards for follow-up treatment and rehabilitation of patients with ventricular assist device (VAD)]. *Clin Res Cardiol Suppl*. 2016 ;11 Suppl 1:2-49. German. doi: 10.1007/s11789-015-0077-x.
22. Cook JL, Colvin M, Francis GS, Grady KL, Hoffman TM, Jessup M, John R, Kiernan MS, Mitchell JE, Pagani FD, Petty M, Ravichandran P, Rogers JG, Semigran MJ, Toole JM; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Radiology and Intervention; and Council on Cardiovascular Surgery and Anesthesia. Recommendations for the Use of Mechanical Circulatory Support: Ambulatory and Community Patient Care: A Scientific Statement From the American Heart Association. *Circulation*. 2017 ;135(25):e1145-e1158. doi: 10.1161/CIR.0000000000000507..

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.